van der Laan LJ - Search Results

1

Antiviral or proviral action of mycophenolic acid in hepatitis B infection?

Pan Q, van Vuuren AJ, van der Laan LJ, Peppelenbosch MP, Janssen HL. Pan Q, et al. Among authors: van vuuren aj, van der laan lj. Hepatology. 2012 Oct;56(4):1586-7. doi: 10.1002/hep.25700. Hepatology. 2012. PMID: 22407546 No abstract available.

2

Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection.

Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, Janssen HL. Stoop JN, et al. Among authors: van der molen rg, van der laan lj. Hepatology. 2005 Apr;41(4):771-8. doi: 10.1002/hep.20649. Hepatology. 2005. PMID: 15791617

3

Flowcytometric quantitation of hepatitis B viral antigens in hepatocytes from regular and fine-needle biopsies.

van der Laan LJ, Taimr P, Kok A, Sprengers D, Zondervan PE, Tilanus HW, Janssen HL. van der Laan LJ, et al. J Virol Methods. 2007 Jun;142(1-2):189-97. doi: 10.1016/j.jviromet.2007.01.027. Epub 2007 Feb 27. J Virol Methods. 2007. PMID: 17328969

4

New therapeutic opportunities for hepatitis C based on small RNA.

Pan QW, Henry SD, Scholte BJ, Tilanus HW, Janssen HL, van der Laan LJ. Pan QW, et al. Among authors: van der laan lj. World J Gastroenterol. 2007 Sep 7;13(33):4431-6. doi: 10.3748/wjg.v13.i33.4431. World J Gastroenterol. 2007. PMID: 17724797 Free PMC article. Review.

5

Combined antiviral activity of interferon-alpha and RNA interference directed against hepatitis C without affecting vector delivery and gene silencing.

Pan Q, Henry SD, Metselaar HJ, Scholte B, Kwekkeboom J, Tilanus HW, Janssen HL, van der Laan LJ. Pan Q, et al. Among authors: van der laan lj. J Mol Med (Berl). 2009 Jul;87(7):713-22. doi: 10.1007/s00109-009-0470-3. Epub 2009 Apr 30. J Mol Med (Berl). 2009. PMID: 19404587 Free PMC article.

6

Prospects of RNAi and microRNA-based therapies for hepatitis C.

Pan Q, Tilanus HW, Janssen HL, van der Laan LJ. Pan Q, et al. Among authors: van der laan lj. Expert Opin Biol Ther. 2009 Jun;9(6):713-24. doi: 10.1517/14712590902989970. Expert Opin Biol Ther. 2009. PMID: 19456206 Review.

7

Experimental models for hepatitis C viral infection.

Boonstra A, van der Laan LJ, Vanwolleghem T, Janssen HL. Boonstra A, et al. Among authors: van der laan lj. Hepatology. 2009 Nov;50(5):1646-55. doi: 10.1002/hep.23138. Hepatology. 2009. PMID: 19670425 Review.

8

Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha.

Pan Q, Metselaar HJ, de Ruiter P, Kwekkeboom J, Tilanus HW, Janssen HL, van der Laan LJ. Pan Q, et al. Among authors: van der laan lj. Liver Transpl. 2010 Apr;16(4):520-6. doi: 10.1002/lt.22032. Liver Transpl. 2010. PMID: 20373462 Free article.

9

AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?

van der Laan LJ, Wang Y, Tilanus HW, Janssen HL, Pan Q. van der Laan LJ, et al. Expert Opin Biol Ther. 2011 Mar;11(3):315-27. doi: 10.1517/14712598.2011.548799. Epub 2011 Jan 5. Expert Opin Biol Ther. 2011. PMID: 21204741 Review.

10

Disturbance of the microRNA pathway by commonly used lentiviral shRNA libraries limits the application for screening host factors involved in hepatitis C virus infection.

Pan Q, de Ruiter PE, von Eije KJ, Smits R, Kwekkeboom J, Tilanus HW, Berkhout B, Janssen HL, van der Laan LJ. Pan Q, et al. Among authors: van der laan lj. FEBS Lett. 2011 Apr 6;585(7):1025-30. doi: 10.1016/j.febslet.2011.02.035. Epub 2011 Mar 2. FEBS Lett. 2011. PMID: 21376045 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

230 results

Search Page